P087 Comparative study of the Quantum Blue rapid test for point of care quantification of faecal calprotectin with an established ELISA method

Background: Faecal calprotectin (FC) has proven its utility as a non-invasive marker for neutrophilic intestinal inflammation. It can be used in the differential diagnosis between functional and organic bowel disease. In Crohn’s disease and ulcerative colitis, FC is a very useful biomarker as it correlates with endoscopic disease activity. The objective of this study is to evaluate the recently launched quantitative immunochromatographic point of care tests (POCT) (Quantum Blue Calprotectin, Buhlmann Laboratories AG) to the currently used ELISA method (Buhlmann Laboratories AG) both numerically and regarding its reliability in distinguishing functional from organic bowel disease. Methods: 142 samples were analysed both with the ELISA and the POCT (normal range (30 300mg/g faeces) or high range (10